touchNEUROLOGY had the pleasure of meeting with Andrew Feigin (Department of Neurology, NYU Grossman School of Medicine, New York City, NY, USA) and Ralf Reilmann (Founding Director, George Huntington Institute, Münster, Germany), to discuss the clinical utility of pridopidine in Huntington’s disease, and the ongoing PROOF-HD study.
The abstract entitled ‘The PROOF-HD Study: Pridopidine’s Outcome on Function in Huntington Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
- Could you tell us a little about pridopidine and its mechanism of action? (1:00)
- What have clinical studies to date taught us about the clinical utility of pridopidine in Huntington’s disease, and what have been the limitations of these studies? (3:43)
- How have previous data been used to optimise the design of the PROOF-HD trial? (12:41)
Disclosures: Andrew Feigin has served as a consultant for NeuExcell, Prilenia, Stealth, and Voyager. Ralf Reilmann has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
Share this Video
Related Videos In Huntington’s Disease
Salvatore Mazzeo, EAN 2022: Huntingtin intermediate alleles and cognitive decline
Huntingtin (HTT) is a gene containing a key region of CAG repeats. Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these IAs on progression of cognitive impairment in patients with subjective cognitive […]
Salvatore Mazzeo, EAN 2022: Cognitive decline – challenges in diagnosis
In this touchNEUROLOGY interview at EAN 2022, Dr Salvatore Mazzeo (University of Florence, Florence, Italy) discusses his study on HTT alleles containing from 27 to 35 CAG repeats – termed intermediate alleles (IAs) – and the effect of these IAs on progression of cognitive impairment in patients with subjective cognitive decline. The abstract titled, Huntingtin […]
Erin Furr-Stimming, AAN 2022: Current treatment landscape for Huntington disease
There are currently no disease-modifying medications for the treatment of Huntington’s disease, and current treatment is entirely dependent on symptomatic therapies. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the current treatment landscape of Huntington’s disease and the limitations of current treatment options. Watch […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!